In brief: Genmab says its experimental antibody–drug conjugate Rina-S outperformed standard chemotherapy in a 584-person Phase III trial for platinum-resistant ovarian cancer. The size of the reported effect is striking, but the announcement supplies hazard ratios rather than the full dataset clinicians need.
Rinatabart sesutecan, or Rina-S, has crossed the most important comparative hurdle in its development so far. On 23 October 2026, Genmab reported that the global RAINFOL-02 trial met both its primary endpoint of progression-free survival and a key secondary endpoint of overall survival. This is a Phase III clinical result, not a laboratory experiment—but it is also a topline company announcement, not an approval or a peer-reviewed publication.
The trial asked a direct treatment question
RAINFOL-02 randomly assigned 584 people with platinum-resistant ovarian cancer to Rina-S or an investigator-selected chemotherapy: paclitaxel, topotecan, pegylated liposomal doxorubicin or gemcitabine. Platinum-resistant means the cancer progressed during platinum treatment or returned soon after it, a setting in which durable responses can be difficult to achieve.
Rina-S is an antibody–drug conjugate, often shortened to ADC. Its antibody binds folate receptor alpha, a protein found at varying levels on many ovarian-cancer cells. A cleavable linker connects that antibody to exatecan, a topoisomerase-I inhibitor designed to damage the DNA of a targeted cell.
According to Genmab’s 23 October announcement, Rina-S reduced the relative risk of disease progression or death by 71% in the intention-to-treat population: hazard ratio 0.29, with a 95% confidence interval from 0.23 to 0.37. For overall survival, the reported hazard ratio was 0.43, corresponding to a 57% relative reduction in the risk of death during the analysed period.
A hazard ratio is not a survival guarantee
Those numbers do not mean 71% of participants avoided progression or that an individual patient’s survival rises by 57%. A hazard ratio compares event rates over time between groups. The absolute benefit depends on the underlying outcomes, which Genmab has not yet supplied in this release.
Missing details include median progression-free and overall survival, response duration, subgroup results and a complete adverse-event table. Genmab says the safety profile was consistent with earlier experience and that no new safety signals emerged. That is useful, but “no new signal” is not the same as mild toxicity. Earlier Rina-S research has reported blood-cell-count reductions and gastrointestinal effects, and the Phase III frequencies and severity will matter.
The broad enrolment strategy matters
The trial included participants regardless of folate-receptor-alpha expression. Its primary analysis set also addressed access to mirvetuximab, an approved FRα-targeted ADC, by requiring eligible patients with high expression to have received it when available. Genmab reported significant progression-free and overall-survival benefits in both that 492-person primary analysis set and the full population.
The trial registry lists RAINFOL-02 as a randomized, open-label, multicentre Phase III study. Open-label means patients and clinicians knew which treatment was given. That design is common when drugs and schedules differ, but blinded independent review of scans becomes important; the protocol includes that as a secondary measure.
Regulation is the next gate
Genmab plans to discuss the results with regulators and submit the data to a medical meeting. A regulator will examine the full efficacy, safety and manufacturing package before deciding whether the drug can be marketed. Until that happens, Rina-S remains investigational.
The result therefore deserves attention without being described as a cure. It turns an encouraging earlier response signal into comparative Phase III evidence and suggests an ADC may outperform several conventional chemotherapy options in a difficult disease setting. The next test is whether the complete dataset confirms a meaningful absolute survival gain with an acceptable burden of side effects.
This article reports research and regulatory developments. It is not medical advice or a treatment recommendation.
Leave a Reply